Amen. Some sanity finally here.
This is clearly a momentum trading stock (with zero fundamentals), but momentum can play both ways. In the short-term, the PPS will remaine extremely volatile in BOTH directions.
ONVO is a very good "story." Many of their proposed markets (e.g. transplants) are decade(s) away from actually being realized. As a person who is in need of a heart transplant, I realize this as much as anyone. I'm a realist and a pragmatist; timing is everything.
The tissue assay market is also much smaller than the $BILLIONS that people have been led to believe. And once we start to see other competitors enter the space, which is inevitable, then you'll see corresponding devaluation of ONVO.
"Stay thirsty my friends, but be careful what you drink."
You've got to be kidding, right?
What prospectus are you referring to?
If true, it tells me something about ONVO management.
ZERO proven products YET, sir... please get your facts straight.
They are shooting for the "end" of 2014 for their first liver assay product.
The amount of "irrational exuberance" with this stock is truly stunning. Speculation for transplant solutions which are decade(s) away.
The liver assay market is actually closer to $200M than the $500M that some have postulated and they won't begin realizing any revenue until late 2014. This company's market cap is currently way too high.
Long-term I'm bullish for this company and 3D bioprinting in general, but there is no "REAL" justification for the current market cap.
Is there a conference call on December 5th? What's happening that day?
Only 4 million shares doesn't dilute the overall float that much.
The biggest concern I have is "when" they will actually be able to release a product and start realizing revenue. I believe we are still 9-12 months off from that.
It would be great if we get Japanese approval before Christmas!
I wouldn't care if my $10 PUTS expired worthless! :)
You can check Option prices right here at Yahoo.
Go to the summary page for KERX and then click on the "Options" link. You'll see date links as headings across the page. Click on the appropriate date you're interested in then check the price for either CALL or PUT options. Right now the asking price for January 2015 $10 PUTS is $2.65/contract.
Definitely do more online research and contract your broker next week before ever attempting to buy Options. They are much riskier than stocks.
You've done very well with KERX. Congrats!
Right now December $10 PUTS for KERX are going for 0.10/contract. If you were to buy 310 contracts at that price that would be $3,100 plus your broker's fees. If the stock drops below $10/share the price of these puts would be at least $1/contract (or higher), as you'd be "in the money."
December $11 PUTS and $12 PUTS are more expensive because they are close to the current stock price. January PUTS (and beyond) are certainly something to look at too, but they are more expensive because there is more time left for the stock to appreciate.
Definitely check with your broker about both PUT and CALL options. Do some online research, first, however. Google is your best friend. :)
Your situation is probably too complex to offer advice in this forum. For starters, we'd need to know the cost basis of all your 31,000 shares.
In general terms, you'd want to buy 310 PUT contracts to cover your 31,000 shares (each contract represents 100 shares). The choice of $10, $11, $12 is based on liquidity concerns (open interest) and what you personally believe the downside to the stock could be if they run into bad news. Generally speaking, most investors sell their options (and take profits or losses) before expiration date, when they either expire worthless or "in the money."
I wish I could help you more, but it's a complicated topic. Maybe someone else can chime in.
If "insurance" is relatively cheap why not get it?
NOTHING is guaranteed in biotech regulatory decisions, my friend.
I'm definitely "betting" on KERX successfully navigating through all of their upcoming catalysts and milestones, but if they run into a snag somewhere along the line I'm protected against loss.
Thanks, and back to you and yours!
Keep your insightful posts coming! Let's knock this one out of the park with the bases loaded!
If they don't need a P3 trial for CKD that should signal to the market that FDA approval is all but assured for both ESRD and CKD?